PPV

Xtreme One Entertainment Announces iNDEMAND as Broadcast Partner for XFC 50

Retrieved on: 
Tuesday, April 2, 2024
PPV, MMA, Television, RP Funding Center, XFC, UFC

DETROIT, April 02, 2024 (GLOBE NEWSWIRE) -- Xtreme One Entertainment, Inc. (OTCPink: CGRW) (the “Company” or “Xtreme One”) and its wholly owned subsidiary XFC Global, Inc. are proud to announce a media rights agreement with iNDEMAND to broadcast XFC 50.

Key Points: 
  • Event goes live at 8:00pm on April 12th from the RP Funding Center in Lakeland, FL
    DETROIT, April 02, 2024 (GLOBE NEWSWIRE) -- Xtreme One Entertainment, Inc. (OTCPink: CGRW) (the “Company” or “Xtreme One”) and its wholly owned subsidiary XFC Global, Inc. are proud to announce a media rights agreement with iNDEMAND to broadcast XFC 50.
  • XFC 50 will air live on April 12, 2024, from Lakeland, Florida, and be broadcast on pay-per-view for $29.95.
  • The broadcast team for XFC 50 features blow-by-blow by Ronnie Duncan, a former sports reporter and anchor in Detroit and other major markets with more than 45 years of broadcast experience.
  • “We are thrilled to partner with iNDEMAND to bring XFC 50 and our exciting card of bouts to more than 60 million homes in the Western Hemisphere,” said Doug Kuiper, President of Xtreme One Entertainment.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, Champalimaud Foundation, Cone Health Women's Hospital, PPV, Glomus tumor, Adenoma, Overdiagnosis, Incidence, Research, Cancer, Hospital, UPMC, Breast, Marie Cassidy, AI, University, Laboratory, MD, Oncology, Medicine, USCAP, OSU, Dysplasia, Brigham and Women's Hospital, Breast cancer, Ohio State University, Pathology, Champalimaud, Stomach, Artificial intelligence, Annual general meeting, NPV, Medical imaging

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Wednesday, March 13, 2024
Senior, Biotechnology, NPV, PMA, Messenger, Next Generation, FDA, Partnership, PPV, Marketing, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Key Points: 
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration
    BERKELEY, US – MAINZ, Germany – March 5, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products.
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Tuesday, March 5, 2024
Senior, Biotechnology, NPV, PMA, Messenger, FDA, Partnership, Marketing, PPV, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression, Medical imaging

In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

Key Points: 
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.
  • “Detecting AA lesions allows for early intervention and significantly increases the chance of successful treatment and survival.
  • The study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA.

Modiv Industrial Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 4, 2024
REIT, Manufacturing, Other Manufacturing, Commercial Building & Real Estate, Construction & Property, CHIPS, Ethos, Air force, YTD, Sale, Tenant, Webcast, Organization, Concussion, Kodak, NFL, Social media, LINK, NBA, CHIPS and Science Act, Pain, Electronics, Pharmacy, Emergency service, Infinite, Motivation, MDV, Nose, Calf, Balance sheet, UFC, Partnership, Life, Fed, Creativity, MLB, Human, Internet, AI, Poultry, Quality of life, Greed, PPV, Thought, Mechanics, Government, Federal Reserve, Risk, Industrial, Real estate investment trust, Painting, Knee, Crutch, Travel, Real estate

Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter revenue of $12.3 million increased $2.3 million year-over-year, or 23%, excluding the 2022 lease termination fee.
  • Fourth quarter AFFO of $4.5 million, or $0.40 per diluted share, exceeding street expectations by $0.05 per share.
  • January 31, 2024, completed the stock distribution of Generation Income Properties, Inc. (NASDAQ: GIPR), common stock to the stockholders of Modiv Industrial.

Endeavor Releases Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
General Sports, General Entertainment, Entertainment, Sports, Diamond, Acquisition, Experience, TKO, PPV, Growth, UFC, PBR, Sale, IMG Academy, Sport, IMG, OpenBet, Webcast, WGA, Major League Soccer, Miami Open, WWE, Barrett-Jackson, Madrid Open, Partnership, Video game

“2023 was a transformational year for Endeavor as we strengthened our positions in sports and entertainment through many of our industry-leading assets,” said Ariel Emanuel, CEO, Endeavor.

Key Points: 
  • “2023 was a transformational year for Endeavor as we strengthened our positions in sports and entertainment through many of our industry-leading assets,” said Ariel Emanuel, CEO, Endeavor.
  • At December 31, 2023, cash and cash equivalents totaled $1.167 billion, compared to $1.338 billion at September 30, 2023.
  • Total debt was $5.028 billion at December 31, 2023, compared to $5.046 billion at September 30, 2023.
  • Endeavor will host an audio webcast to discuss its results and provide a business update at 5 a.m. PT / 8 a.m.

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction

Retrieved on: 
Tuesday, February 13, 2024
ADAP, SAN, Real-time, Doctor of Philosophy, NPV, PPV, Laboratory developed test, Risk, Autoantibody, Carolyn Bertozzi, Risk assessment, CLIA, RBA, T1D, CAP, NIDDK, Public, Pharmaceutical industry

Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.

Key Points: 
  • Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.
  • This pivotal study underscores the ADAP assay's ability to detect islet autoantibodies, which are indicative of a high risk of progression to clinical T1D.
  • Dr. Jason Tsai, PhD, CTO of Enable Biosciences, elaborates on the significance of the findings: "These study results reinforce the strength of our ADAP technology in early T1D detection.
  • For more insights into Enable Biosciences and the impact of their ADAP technology, please visit www.enablebiosciences.com .

Fubo Makes Strategic Investment in BKFC, Will Stream BKFC 57 Live Event on February 2

Retrieved on: 
Friday, January 26, 2024
Technology, General Sports, Sports, Entertainment, Telecommunications, Audio, Video, Events, Concerts, General Entertainment, Internet, BKFC, FuboTV, Social media, Multimedia, Boxing, Partnership, History, Bare Knuckle Fighting Championship, Trout, PPV, MMA, Gandler

View the full release here: https://www.businesswire.com/news/home/20240126376160/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240126376160/en/
    The strategic investment expands the companies’ current partnership, which includes live distribution rights on Fubo Sports, Fubo’s FAST (free ad-supported streaming TV) linear network, and Pay-Per-View (PPV).
  • Through the expanded partnership, Fubo will stream select BKFC’s live events, including BKFC 57 on February 2, 2024, live from the Seminole Hard Rock Hotel and Casino in Hollywood, FL.
  • “Fubo is committed to bringing consumers an aggregated content experience that includes the widest choice of live sports programming,” said Gandler.
  • “The singularity of bare knuckle fighting has already made BKFC an important strategic partner for our Fubo Sports linear channel.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.